EXAPHARMA’s source plasma undergoes many quality checks before it is released for further manufacturing. Every plasma unit undergoes documented transmissible disease marker testing, interdepartmental review and release before it is made available to the fractionator.
EXAPHARMA complies with national and international safety standards for all plasma-derived therapeutics. Our donation centres are inspected and audited regularly by Health Canada. The centres are also subject to inspection by international regulations.
Quality control measures play a critical role in contributing to the high quality source plasma provided by EXAPHARMA.